You have 7 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PCSK9i

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic

Recruiting
  • Atherosclerosis
  • Aortic Valve Disease
  • Thrombotic assessment
  • Measurement of Lp(a)
  • Stevenage, United Kingdom
    East and North Herts NHS Trust
Nov 6, 2023

Hypercholesterolaemia Trial (MK-0616)

Not yet recruiting
  • Hypercholesterolaemia
  • (no location specified)
Jul 12, 2023

Nephrotic Syndrome Trial in Dallas (Alirocumab, Alirocumab , Atorvastatin)

Terminated
  • Nephrotic Syndrome
  • Dallas, Texas
    DallasVAMC
Aug 17, 2022

Vasculopathy Trial in Stanford (alirocumab, )

Enrolling by invitation
  • Vasculopathy
  • alirocumab
  • placebo
  • Stanford, California
    Stanford University
May 22, 2022

Arteriosclerosis, Hypercholesterolaemia Trial (MK-0616, Placebo)

Not yet recruiting
  • Arteriosclerosis
  • Hypercholesterolaemia
  • (no location specified)
Aug 17, 2023

Atherosclerotic Cardiovascular Disease Trial in Worldwide (NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for

Active, not recruiting
  • Atherosclerotic Cardiovascular Disease
  • NNC0385-0434 A 15 mg
  • +6 more
  • Palm Springs, California
  • +42 more
Mar 21, 2022

Acute Myocardial Infarction Trial in Shanghai (alirocumab, conventional treatment)

Recruiting
  • Acute Myocardial Infarction
  • Shanghai, Shanghai, China
  • +3 more
Oct 31, 2022

Hypercholesterolemia, Familial Hypercholesterolemia Trial (MK-0616, Placebo)

Not yet recruiting
  • Hypercholesterolemia
  • Familial Hypercholesterolemia
  • (no location specified)
Jul 10, 2023

Acute Coronary Syndrome Trial in Nanjing (Statin, PCSK9 inhibitor)

Not yet recruiting
  • Acute Coronary Syndrome
  • Nanjing, Jiangsu, China
    First Affiliated Hospital of Nanjing Medical University
Mar 17, 2022

Hypercholesterolemia, Familial Hypercholesterolemia Trial (MK-0616, Placebo)

Not yet recruiting
  • Hypercholesterolemia
  • Familial Hypercholesterolemia
  • (no location specified)
Jul 10, 2023

Aortic Stenosis Trial in Beijing (PCSK9 inhibitor and Statin, Statin)

Recruiting
  • Aortic Stenosis
  • PCSK9 inhibitor and Statin
  • Statin
  • Beijing, Beijing, China
    Beijing Anzhen Hospital, Capital Medical University
Sep 4, 2021

Prognosis of Ischemic Stroke Due to Large-artery Atherosclerosis

Recruiting
  • Ischemic Stroke
  • Large-Artery Atherosclerosis (Embolus/Thrombosis)
  • carotid artery stenting
  • +6 more
  • Wuhan, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 31, 2022

In-stent Restenosis, Major Adverse Cardiovascular Events Trial in Beijing (PCSK9 inhibitor, Statin)

Recruiting
  • In-stent Restenosis
  • Major Adverse Cardiovascular Events
  • Beijing, Beijing, China
    Beijing Anzhen Hospital
Jan 16, 2023

Proprotein Convertase Subtilisin Kexin 9 in Rheumatoid Arthritis

Recruiting
  • PCSK9
  • Enzyme-linked immunosorbent assay for PCSK9
  • Harbin, Heilongjiang, China
  • +1 more
Dec 30, 2021

Stable Coronary Disease Trial (Evolocumab)

Not yet recruiting
  • Stable Coronary Disease
  • (no location specified)
Dec 16, 2021

Cholesterol; Metabolic Disorder, Lipoproteinemia Trial in Nantes (infusion of tracer [5,5,5-2H3] -L-leucine)

Completed
  • Cholesterol; Metabolic Disorder
  • Lipoproteinemia
  • infusion of tracer [5,5,5-2H3] -L-leucine
  • Nantes, France
    Nantes University Hospital
Feb 22, 2022

Healthy Subjects, Pharmacokinetics, Pharmacodynamics Trial in West Bend (Evolocumab, Alirocumab, Placebo)

Completed
  • Healthy Subjects
  • +2 more
  • Evolocumab
  • +2 more
  • West Bend, Wisconsin
    Spaulding Clinical Research
Aug 16, 2021

Efficacy of Treatment With PCSK9 Inhibitors in Italy

Completed
  • Hypercholesterolemia
  • Repatha (evolocumab); Praluent (alirocumab)
  • Bari, Italy
  • +8 more
Jun 20, 2022

Hypercholesterolemia, Insulin Resistance, Insulin Secretion Trial in Tuebingen (Lowering cholesterol concentrations by PCSK-9

Recruiting
  • Hypercholesterolemia
  • +2 more
  • Lowering cholesterol concentrations by PCSK-9 inhibitor
  • Tuebingen, Germany
    University of Tuebingen, Department of Internal Medicine IV
Aug 24, 2022

Coronary Artery Disease, Atherosclerosis of Coronary Artery Trial in Nijmegen (Evolocumab 140 MG/ML [Repatha])

Recruiting
  • Coronary Artery Disease
  • Atherosclerosis of Coronary Artery
  • Evolocumab 140 MG/ML [Repatha]
  • Nijmegen, Gelderland, Netherlands
    Radboud University Medical Center
Jan 11, 2022

Hereditary Spastic Paraplegia Type 5 Trial in Fuzhou (evolocumab)

Recruiting
  • Hereditary Spastic Paraplegia Type 5
  • Fuzhou, China
    Department of Neurology , First Affiliated Hospital Fujian Medic
Nov 21, 2021

Pre-analytical Influences on a Blood Test Study

Not yet recruiting
  • IBS - Irritable Bowel Syndrome
  • Blood test
  • Analyses of samples
  • (no location specified)
Jun 22, 2022

Efficacy and Safety, Heterozygous Familial Hypercholesterolemia, PCSK9 Trial in Shenzhen (protein convertase subtilisin/kexin

Active, not recruiting
  • Efficacy and Safety
  • +2 more
  • protein convertase subtilisin/kexin type 9 inhibitor
  • Shenzhen, Guangdong, China
    xili People's Hospital
Aug 24, 2021

Homozygous Familial Hypercholesterolemia Trial in Beijing (IBI306)

Active, not recruiting
  • Homozygous Familial Hypercholesterolemia
  • IBI306
  • Beijing, China
    Beijing Anzhen Hospital, Capital Medical University
Sep 12, 2022

Type 2 Diabetes Trial in Helsinki (Evolocumab)

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Helsinki, Finland
    Helsinki University Hospital, Biomedicum 2U
Oct 28, 2021